Branched vascular network architecture: A new approach to lung assist device technology

Hoganson, David M.; Anderson, Jennifer L.; Weinberg, Eli F.; Swart, Eric; Orrick, Brian K.; Borenstein, Jeffrey T.; Vacanti, Joseph P.

doi:10.1016/j.jtcvs.2010.02.062

Cited by 42 publications

(50 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, patients with severe respiratory disabilities that require whole lung transplant must usually wait for over a year until a donor is found [9]. For such cases, a long-term solution is needed: a stable and permanent AL that can improve life quality and reduce mortality while awaiting transplant [10, 11]. …”

Section: Artificial Lungsmentioning

confidence: 99%

“…In addition, blood flow pathways within some AL designs are nonphysiological; they feature relatively high shear forces upon flowing blood that are hard to predict or control. These forces can cause damage to red blood cells (RBCs) such as platelet activation, stimulate inflammatory responses, and give rise to blood clotting, all of which result in higher morbidity and mortality rates [10, 12]. Finally, thrombus formation requires anticoagulant administration which can cause bleeding and electrolyte-related imbalance that call for additional medical care [12].…”

Section: Artificial Lungsmentioning

confidence: 99%

“…Microfabricated systems also allow for easier prediction and control over flow parameters, including shear stresses created during blood flow within the device. Indeed, computational fluid dynamics (CFDs) are commonly used to carefully design the delicate architecture of a microfluidic AL device [9, 10, 12, 14]. …”

Section: Artificial Lungsmentioning

confidence: 99%

“…Hoganson et al [10] emphasized the importance of utilizing such architectures, compared to straight channels, to enlarge the surface area available and maximize the gas exchange rate. Blood flow was introduced through a dense, branching network of microfluidic channels with a thin gas-permeable membrane separating the channels from an air chamber, representing the alveolar space.…”

Section: Artificial Lungsmentioning

confidence: 99%

See 3 more Smart Citations

Respiratory Physiology on a Chip

2012

View full text Add to dashboard Cite

Our current understanding of respiratory physiology and pathophysiological mechanisms of lung diseases is often limited by challenges in developing in vitro models faithful to the respiratory environment, both in cellular structure and physiological function. The recent establishment and adaptation of microfluidic-based in vitro devices (μFIVDs) of lung airways have enabled a wide range of developments in modern respiratory physiology. In this paper, we address recent efforts over the past decade aimed at advancing in vitro models of lung structure and airways using microfluidic technology and discuss their applications. We specifically focus on μFIVDs covering four major areas of respiratory physiology, namely, artificial lungs (AL), the air-liquid interface (ALI), liquid plugs and cellular injury, and the alveolar-capillary barrier (ACB).

show abstract

Section: Artificial Lungsmentioning

confidence: 99%

Section: Artificial Lungsmentioning

confidence: 99%

Section: Artificial Lungsmentioning

confidence: 99%

Section: Artificial Lungsmentioning

confidence: 99%

See 2 more Smart Citations

Respiratory Physiology on a Chip

2012

View full text Add to dashboard Cite

show abstract

“…The control of fluid mechanics and mass transport over this wide range of dimensions has been used to study bioactive molecules and therapeutics in cardiovascular research and tissue engineering [39]. Sophisticated devices have recently been fabricated to reproduce a lung assist apparatus allowing the blood being perfused within the microchannels to be oxygenated by flowing through many parallel capillary-like channels analogous to the native lung architecture [40]. Although optimization of the gas transfer membrane and characterization of the blood flow in the device are still needed, this is a good example demonstrating the potential of microfabrication technologies to generate vascularized platforms for tissue engineering.…”

Section: Introductionmentioning

confidence: 99%

Application of microtechnologies for the vascularization of engineered tissues

et al. 2011

View full text Add to dashboard Cite

Recent advances in medicine and healthcare allow people to live longer, increasing the need for the number of organ transplants. However, the number of organ donors has not been able to meet the demand, resulting in an organ shortage. The field of tissue engineering has emerged to produce organs to overcome this limitation. While tissue engineering of connective tissues such as skin and blood vessels have currently reached clinical studies, more complex organs are still far away from commercial availability due to pending challenges with in vitro engineering of 3D tissues. One of the major limitations of engineering large tissue structures is cell death resulting from the inability of nutrients to diffuse across large distances inside a scaffold. This task, carried out by the vasculature inside the body, has largely been described as one of the foremost important challenges in engineering 3D tissues since it remains one of the key steps for both in vitro production of tissue engineered construct and the in vivo integration of a transplanted tissue. This short review highlights the important challenges for vascularization and control of the microcirculatory system within engineered tissues, with particular emphasis on the use of microfabrication approaches.

show abstract

Miniaturization of Artificial Lungs toward Portability

Dabaghi

Rochow

Saraei

et al. 2020

Adv Materials Technologies

View full text Add to dashboard Cite

Artificial lungs support patients undergoing open‐heart surgery, organ transplantation, and in serious lung injury by providing oxygenation support through an extracorporeal circuit. Some patients require partial support for durations of a few weeks or months even after the surgery. Therefore, a portable or wearable lung assist device which can be operated for several weeks with minimum maintenance would be ideal. Miniaturization of blood oxygenators, using microfluidic technology, is a promising avenue for the realization of such portable artificial lungs. The microfluidic blood oxygenators (MBOs) are also suitable for neonates with respiratory failure due to their low priming volume and pressure drop. Herein, the history of microfluidic oxygenator development and recent progress in miniaturized artificial lungs are discussed. The MBOs have made significant advances in 1) reducing device size, 2) providing biomimetic blood flow paths, 3) enabling operation in room air, and 4) operating without the need of an external pump. Recent work has demonstrated throughput of up to 150 mL min‐1 of blood and oxygen transfer rate of 60 mL O2 per L of blood. The challenges faced by this technology in practical applications as well as future improvements to meet the requirements for older neonates and even adults are also presented.

show abstract

Branched vascular network architecture: A new approach to lung assist device technology

Cited by 42 publications

References 22 publications

Respiratory Physiology on a Chip

Respiratory Physiology on a Chip

Application of microtechnologies for the vascularization of engineered tissues

Miniaturization of Artificial Lungs toward Portability

Contact Info

Product

Resources

About